Allogene Therapeutics Inc (ALLO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Allogene Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 1.90 $ — 43% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -100.0% failed
- More than 10% revenue growth is expected for the coming year 216,118.5% passed
- Share count grows by less than 3% a year 15.5% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 167 m net cash passed
- Operating cash flow covers the profits of the last three years 188 m failed
- Return on capital at 15% or higher, or up versus two years ago -54.0% failed
- Insiders hold at least 10% or are net buyers 11.0% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 373.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 14
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.61 | -0.66 – -0.58 | 0 | 28.8% | 5 |
| 12/31/2027 | -0.68 | -1.00 – -0.42 | 15 | -12.5% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.16 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.28 | – | 0 | – | – | -37 | -37 |
| 2025: Q1 | -0.28 | – | 0 | -100.00 | – | -53 | -53 |
| 2025: Q2 | -0.23 | – | 0 | – | – | -39 | -39 |
| 2025: Q3 | -0.19 | – | 0 | – | – | -30 | -30 |
| 2025: Q4 | -0.18 | – | 0 | – | – | -28 | -28 |
| 2026: Q1 | -0.18 | – | 0 | – | – | -13 | -13 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 0 | 0 | 0 | 0.00 | -45 | 0 | 0 |
| 2018 | 0 | -193 | -212 | -2.36 | -45 | 703 | 774 |
| 2019 | 0 | -202 | -185 | -1.83 | -137 | 629 | 718 |
| 2020 | 38 | -258 | -233 | -1.94 | -115 | 1,080 | 1,228 |
| 2021 | 38 | -256 | -245 | -1.80 | -185 | 925 | 1,051 |
| 2022 | 0 | -335 | -330 | -2.30 | -221 | 667 | 822 |
| 2023 | 0 | -328 | -327 | -2.09 | -238 | 512 | 643 |
| 2024 | 0 | -273 | -258 | -1.32 | -200 | 422 | 549 |
| 2025 | 0 | -207 | -191 | -0.87 | -149 | 293 | 416 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Allogene Therapeutics, Inc., ein immunonkologisches Unternehmen in der klinischen Phase, entwickelt und vermarktet gentechnisch veränderte allogene T-Zell-Therapien zur Behandlung von Krebs und Autoimmunerkrankungen.
| Employees | 150 |
|---|---|
| Headquarters | South San Francisco, CA |
| Address | 210 East Grand Avenue, 94080 South San Francisco, United States |
| Phone | 650 457 2700 |
| Website | allogene.com |
| IPO Date | 11. Oct 2018 |
| ISIN | US0197701065 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder & Executive Chairman | 1949 |
| Zachary J. Roberts M.D., Ph.D. | President, CEO & Director | 1978 |
| Joshua A. Kazam | Co-Founder & Director | 1977 |
| David D. Chang M.D., Ph.D. | Co-Founder & Director | 1960 |
| Geoffrey M. Parker | Executive VP & CFO | 1965 |
| Benjamin M. Beneski | Senior VP & Chief Technical Officer | 1977 |
| Earl M. Douglas Esq. | Senior VP, General Counsel, Compliance Officer & Corporate Secretary | 1963 |
| Susan R. Lundeen | Chief People Officer | 1966 |
| Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer | – |
| Annie Yoshiyama | SVP & Corporate Controller | 1984 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 21. Apr 2026 | Annie Yoshiyama | SVP | Sell | 9,586 | 2.31 | 22,144 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.